Thymosin beta-4 is a 43-amino-acid endogenous actin-sequestering peptide encoded by the TMSB4X gene. This lesson works through its mechanisms, the available human evidence, and where it stands clinically and from a regulatory standpoint. The peptide carries emerging preclinical signals and Phase 2 human data across wound healing, cardiac repair, and ophthalmology, alongside ongoing Phase 3 work in neurotrophic keratopathy.

A practical caution sits up front: synthetic thymosin beta-4 is sold commercially under the name TB500, and the two are treated as functionally identical here. The peptide is not FDA approved, is prohibited by WADA, and has been removed from 503A and 503B compounding, so sourcing and quality vary widely.

How it works

The primary mechanism is sequestration of G-actin, where the peptide complexes with G-actin monomers and limits spontaneous polymerization into F-actin. Dr. Seeds offers the image of a tank tread: the G-actin monomers are continuously laid down so the track keeps moving forward, supporting cell migration and tissue repair. Through this central node, the peptide intersects multiple signaling cascades, including PI3K/AKT/eNOS, NF-kB inhibition, HIF-1 alpha stabilization, ErbB2/Raf1, TGF-beta/SMAD, Wnt/beta-catenin, Notch, and MAPK/ERK.

On the immune side, it blocks IkB phosphorylation and p65 nuclear translocation, suppressing NF-kB transcription and downstream cytokines such as TNF-alpha, IL-1 beta, IL-8, COX-2, and iNOS. Most of these pathway findings are in vitro, and there is no direct evidence for influence on AMPK, mTOR, NAD, sirtuins, NRF2, FOXO, JAK/STAT, hedgehog, or cyclic AMP/PKA.

What the human evidence supports

IV pharmacokinetics are well documented through Phase 1 and 2 trials: a half-life of roughly one to two hours, dose-proportional behavior, no accumulation after 10 to 14 days, and immunogenicity under one percent. The strongest clinical signals are topical, with reduced corneal staining and symptoms in dry eye and accelerated chronic wound healing in responders. A randomized IV trial in post-infarct patients showed subgroup changes but no overall significant difference.

Several things remain unconfirmed. There is no subcutaneous or oral PK data, no long-term safety beyond 14 days of IV use, and no formal drug interaction studies. The metabolite ACSDKP is degraded by ACE, so ACE inhibitors may elevate it, a point to note when these agents are used together. Because the peptide is proangiogenic, it may counteract anti-angiogenic therapy, and active malignancy is treated as a relative contraindication pending further evaluation.

Key clinical points

• Thymosin beta-4 sequesters G-actin as its core mechanism, sitting at the intersection of repair, anti-inflammatory, and angiogenic pathways, largely on in vitro evidence.
• It is not FDA approved, is WADA prohibited, and has been removed from 503A/503B compounding; the synthetic form is marketed as TB500.
• Documented human data is IV and topical; subcutaneous and oral dosing lack PK support, and long-term safety beyond 14 days is unconfirmed.
• ACE inhibitors may elevate the ACSDKP metabolite, and proangiogenic activity warrants caution with anti-angiogenic therapy and active malignancy.
• Suggested monitoring includes CBC with differential, comprehensive metabolic panel, cytokines, and cardiac and cancer-screening context where angiogenic potential is relevant.